✦ LIBER ✦

Absence of mutations in the tyrosine kinase and juxtamembrane domains of C-FMS gene in chronic myelomonocytic leukemia (CMML)

✍ Scribed by Esperanza Such; Jose Cervera; Ana Valencia; Zaida Garcia-Casado; M. Leonor Senent; Miguel A. Sanz; Guillermo F. Sanz

Book ID: 104041028
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 93 KB
Volume: 33
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2009.03.018

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Complexity of BCR-ABL kinase domain muta

Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia

✍ Dushyant Verma; Carmen Fava; Hagop Kantarjian; Jorge Cortes 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

Internal tandem duplication and Asp835 m

Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia : Correlation with molecular subtypes of PML/RARα and clinical features

✍ Lee-Yung Shih; Ming-Chung Kuo; Der-Cherng Liang; Chein-Fuang Huang; Tung-Liang L 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 2 views

## Abstract ## BACKGROUND The clinical relevance of mutations of the __FMS__‐like tyrosine kinase 3 (__FLT3__) gene in specific cytogenetic subgroups is not clear. The authors examined internal tandem duplication (ITD) and Asp835 mutations of __FLT3__ in patients with acute promyelocytic leukemia

Practical advice for determining the rol

Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

✍ Elias Jabbour; Susan Branford; Giuseppe Saglio; Dan Jones; Jorge E. Cortes; Hago 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 288 KB 👁 1 views

## Abstract Data demonstrating the superiority of nilotinib over imatinib in the frontline treatment of chronic myeloid leukemia (CML) and ongoing studies with dasatinib and bosutinib are rapidly changing the treatment landscape for CML. In this review, the authors discuss currently available thera